References

  1. Hagège AA, Germain DP. Adult patients with Fabry disease: what does the cardiologist need to know? Heart. 2015 Jun; 101(12): 916-8. PubMed | Google Scholar

  2. Elliott P et al. Prevalence of Anderson- Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart. 2011 Dec; 97(23): 1957-60. Google Scholar

  3. Hagege AA et al. Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study. Heart. 2011 Jan; 97(2): 131-6. Google Scholar

  4. Elliott PM et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014 Oct 14; 35(39): 2733-79.

  5. Linhart A, Palecek T, Bultas J et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J. 2000 Jun; 139(6): 1101-8. PubMed | Google Scholar

  6. Kampmann C, Wiethoff CM, Perrot A, Beck M, Dietz R, Osterziel KJ. The heart in Anderson Fabry disease. Z Kardiol. 2002 Oct; 91(10): 786-95. PubMed | Google Scholar

  7. Ashrafian H et al. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet. 2003 May; 19(5): 263-8. PubMed | Google Scholar

  8. Uchino M, Uyama E, Kawano H et al. A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier. Acta Neuropathol. 1995; 90(3): 334-8. PubMed | Google Scholar

  9. Nakao S, Takenaka T, Maeda M et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med. 1995 Aug 3; 333(5): 288-93. PubMed | Google Scholar

  10. Chimenti C, Pieroni M, Morgante E et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004 Aug 31; 110(9): 1047-53. PubMed | Google Scholar

  11. Igawa O, Miake J, Hisatome I. Ventricular tachycardias and dilated cardiomyopathy caused by Fabry disease. Pacing Clin Electrophysiol. 2005 Oct; 28(10): 1142-3. PubMed | Google Scholar

  12. Schiffmann R, Kopp JB, Austin HA 3rd et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001 Jun 6; 285(21): 2743-9. PubMed | Google Scholar

  13. Hopkin RJ, Bissler et al. comparative evaluation of alpha galactosidase A infusion for treatment of Fabry disease. Genet Med. 2003 May-Jun; 5(3): 144-53. PubMed | Google Scholar

  14. Lee K, Jin K et al. A Biochemical and pharmacological comparaison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology. 2003 Apr; 13(4): 305-13. PubMed | Google Scholar

  15. Waldek S. PR interval and the response to enzyme-replacement therapy for Fabry’s disease. N Engl J Med. 2003 Mar 20; 348(12): 1186-7. PubMed | Google Scholar